Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program
Titan Pharmaceuticals (NASDAQ: TTNP) announced positive results for its kappa opioid agonist peptide, JT-09, showing high potency for the human kappa-opioid receptor. The studies indicated that JT-09 is as effective as difelikefalin in reducing itch in mouse models. With potential therapeutic concentrations deliverable via ProNeura implants for over six months, Titan plans to advance to a non-clinical proof-of-concept study. These developments aim to address chronic pruritus, a challenging condition for effective treatment.
- JT-09 shows high potency and specificity for kappa-opioid receptors.
- Studies indicate JT-09 is equally effective as difelikefalin in itch reduction.
- ProNeura implants may deliver therapeutic concentrations for over six months.
- None.
SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potency and specificity for the human kappa-opioid receptor ("KOR"). JT-09 is being developed for use in combination with Titan's ProNeura® long-term, continuous drug delivery technology for the treatment of moderate-to-severe chronic pruritus (itch).
The KOR potency studies used the cAMP Hunter™ assay with cloned human mu, delta and kappa opioid receptors. In addition, in studies conducted in collaboration with Charles Chavkin, Ph.D., Allan and Phyllis Treuer Endowed Chair of Pain Research and Professor, Department of Pharmacology, at the University of Washington Health Sciences Center, Seattle, WA, pretreatment with JT-09 or with difelikefalin (which is being developed as Korsuva™ by Cara Therapeutics, Inc.) were observed to be equally potent in reducing scratching and grooming bouts when injected subcutaneously (0.3 mg/kg) in a 5'-guanidinonaltrindole (5'-GNTI) itch-induced mouse model.
"Pilot pharmacokinetic studies in rats previously indicated that subcutaneous placement of ProNeura implants containing JT-09 could deliver potentially therapeutic concentrations of this KOR agonist for up to six months or longer," said Kate Beebe DeVarney, Ph.D., President and Chief Operating Officer of Titan.
Dr. Beebe DeVarney continued, "These additional early positive data provide strong support for us to move forward with our planned non-clinical proof-of-concept study of JT-09 ProNeura implants in this animal itch model. This is an important next step for Titan towards developing a new treatment modality for moderate-to-severe chronic pruritus that is effective, patient-friendly and convenient."
About Chronic Pruritus
Chronic pruritus is an unpleasant sensation resulting in a need to scratch that lasts more than 6 weeks. It is a prevalent and bothersome symptom associated with both cutaneous and systemic conditions. Due to its complex pathogenesis and numerous contributing factors, effective treatment of chronic pruritus therapy remains challenging.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is a development-stage biotechnology company developing proprietary therapeutics using its clinically proven ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the winding down of U.S. commercial activities related to Probuphine, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Korsuva is a trademark of Cara Therapeutics, Inc.
CONTACT:
Stephen Kilmer
Investor Relations
(650) 989-2215
skilmer@titanpharm.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/positive-early-study-results-help-pave-wave-for-titan-pharmaceuticals-to-move-forward-with-its-jt-09-proneura-development-program-301218731.html
SOURCE Titan Pharmaceuticals, Inc.
FAQ
What are the results of Titan Pharmaceuticals' JT-09 studies?
What is the intended use of Titan's JT-09?
What is the significance of the ProNeura technology for Titan Pharmaceuticals?
What does chronic pruritus mean?
When did Titan Pharmaceuticals announce the JT-09 study results?
